Mike Hollan

Pfizer and J&J supply chain experts on why health authorities now ask not just whether your quality systems work — but how fast you can adapt.

CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.

Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.

CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.

Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.

CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.

MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.

Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.

Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.

Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.

Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.

Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.

Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.

Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.

Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.

Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.

Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.

Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.

Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.

Dr. Elena Christofides on why cortisol dysregulation may be the hidden reason GLP-1s fail — and what to do when patients don't respond.

Inizio's Elaine Ferguson on why connecting talent across 10,500 employees and four business units is fundamental to delivering client value.

Dr. Elena Christofides on why patients who don't respond to diabetes medications deserve a diagnostic workup — not a non-adherence label.

Dr. Elena Christofides on why treatment failure in diabetes should trigger a cortisol screen — not an assumption of non-adherence.

Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction.

Dr. Elena Christofides on why cortisol dysregulation may explain why so many patients fail to respond to GLP-1 and incretin therapies.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Christian Thienel on the oral IBD mechanisms generating the most excitement — SIK2, oral IL-23, TYK2 — and why multiple could succeed.

Carelon Research's Mark Cziraky on why analyzing RWD in place — rather than licensing it out — is reshaping how evidence gets generated.